Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
National Cancer Center Hospital East · Yonsei University · +20 more institutions
Indexed incrossref
Abstract
No abstract available for this paper.
Citation impact
1,223
total citations
- FWCI
- 57.67
- Percentile
- 100%
- References
- 33
Citations per year
Authors
18Topics & keywords
Topics
Keywords
- Refractory (planetary science)
- Nivolumab
- Chemotherapy
- Medicine
- Internal medicine
- Oncology
- Open label
- Esophageal squamous cell carcinoma
UN Sustainable Development Goals
- No poverty
No related works found for this paper.